RAPT Therapeutics, Inc.

NASDAQ:RAPT

1.25 (USD) • At close March 12, 2025
Bedrijfsnaam RAPT Therapeutics, Inc.
Symbool RAPT
Munteenheid USD
Prijs 1.25
Beurswaarde 165,008,750
Dividendpercentage 0%
52-weken bereik 0.789 - 9.654
Industrie Biotechnology
Sector Healthcare
CEO Dr. Brian Russell Wong M.D., Ph.D.
Website https://www.rapt.com

An error occurred while fetching data.

Over RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type

Vergelijkbare Aandelen

IRadimed Corporation logo

IRadimed Corporation

IRMD

52.84 USD

Nuvalent, Inc. logo

Nuvalent, Inc.

NUVL

72.52 USD

Kinnate Biopharma Inc. logo

Kinnate Biopharma Inc.

KNTE

2.65 USD

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.55 USD

Leafly Holdings, Inc. logo

Leafly Holdings, Inc.

LFLY

0.269 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

0.794 USD

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

38.57 USD

Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc

CNTA

17.06 USD

Rallybio Corporation logo

Rallybio Corporation

RLYB

0.659 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)